Celyad Announces Third Quarter 2017 Business Update

Celyad Announces Third Quarter 2017 Business Update

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad Reports First Half 2017 Financial Results and Operational Progress

Celyad Reports First Half 2017 Financial Results and Operational Progress

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad Announces First Quarter 2017 Business Update

Celyad Announces First Quarter 2017 Business Update

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017